{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:27:15Z","timestamp":1789770435342,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1124\/jpet.123.002052","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:00:10Z","timestamp":1709834410000},"page":"219-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pharmacologic Characterization of Substituted Nitazenes at \u03bc, \u03ba, and \u0394 Opioid Receptors Suggests High Potential for Toxicity"],"prefix":"10.1016","volume":"389","author":[{"given":"Laura B.","family":"Kozell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Eshleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Wolfrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley H.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Benware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Schmachtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamryn A.","family":"Schutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Schutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Janowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7080-3509","authenticated-orcid":false,"given":"Atheir I.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.002052_bib1","series-title":"Provisional drug overdose death counts.","author":"Ahmad","year":"2024"},{"key":"10.1124\/jpet.123.002052_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31264","article-title":"Naloxone use in novel potent opioid and fentanyl overdoses in emergency department patients","volume":"6","author":"Amaducci","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1124\/jpet.123.002052_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF02353862","article-title":"Comparative physiological pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models","volume":"22","author":"Bj\u00f6rkman","year":"1994","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.123.002052_bib4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/15563650.2022.2084406","article-title":"Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose","volume":"60","author":"Calello","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1124\/jpet.123.002052_bib5","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.002052_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109263","article-title":"Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent \u03bc-opioid receptor agonists","volume":"221","author":"De Luca","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.002052_bib7","series-title":"Schedules of controlled substances: temporary placement of fentanyl-related substances in Schedule I. Temporary amendment; temporary scheduling order.","year":"2018"},{"key":"10.1124\/jpet.123.002052_bib8","series-title":"Placement of isotonitazene in Schedule I.","year":"2021"},{"key":"10.1124\/jpet.123.002052_bib9","series-title":"Temporary placement of butonitazene, etodesnitazene, flunitazene, metodesnitazene, metonitazene, npyrrolidino etonitazene, and protonitazene in Schedule I.","year":"2022"},{"key":"10.1124\/jpet.123.002052_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-3565(25)20761-3","article-title":"Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor","volume":"278","author":"Emmerson","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002052_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.002052_bib12","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00213-023-06451-2","article-title":"Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u2018nitazene\u2019 opioids associated with human overdose","volume":"240","author":"Glatfelter","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.002052_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/BF02161116","article-title":"[Synthesis of analgesically active benzimidazole derivatives with basic substitutions]","volume":"13","author":"Hunger","year":"1957","journal-title":"Experientia"},{"key":"10.1124\/jpet.123.002052_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/jpet.122.001454","article-title":"Pharmacologic activity of substituted tryptamines at 5-hydroxytryptamine (5-HT)2A receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and serotonin transporter","volume":"385","author":"Kozell","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002052_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jat\/bkaa016","article-title":"Isotonitazene quantitation and metabolite discovery in authentic forensic casework","volume":"44","author":"Krotulski","year":"2020","journal-title":"J Anal Toxicol"},{"key":"10.1124\/jpet.123.002052_bib16","first-page":"505","article-title":"[Benzimidazole and its derivatives--from fungicides to designer drugs. A new occupational and environmental hazards]","volume":"63","author":"Lutz","year":"2012","journal-title":"Med Pr"},{"key":"10.1124\/jpet.123.002052_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107121","article-title":"Mu-opioid receptor selective superagonists produce prolonged respiratory depression","volume":"26","author":"Malcolm","year":"2023","journal-title":"iScience"},{"key":"10.1124\/jpet.123.002052_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000970","article-title":"Acute intoxications and fatalities associated with benzimidazole opioid (nitazene analog) use: a systematic review","volume":"44","author":"Montanari","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1124\/jpet.123.002052_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAF.0000000000000787","article-title":"Proliferation of novel synthetic opioids in postmortem investigations after core-structure scheduling for fentanyl-related substances","volume":"43","author":"Papsun","year":"2022","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1124\/jpet.123.002052_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ADM.0000000000000775","article-title":"Emerging characteristics of isotonitazene-involved overdose deaths: a case-control study","volume":"15","author":"Shover","year":"2021","journal-title":"J Addict Med"},{"key":"10.1124\/jpet.123.002052_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.123.002052_bib22","series-title":"Drug overdose deaths in the United States, 2001\u20132021. NCHS Data Brief, no 457.","author":"Spencer","year":"2022"},{"key":"10.1124\/jpet.123.002052_bib23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/sj.bjp.0707672","article-title":"Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors","volume":"153","author":"Strange","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.002052_bib24","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"Toll","year":"1998","journal-title":"NIDA Res Monogr"},{"key":"10.1124\/jpet.123.002052_bib25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/jpet.120.265561","article-title":"Fentanyl but not morphine interacts with nonopioid recombinant human neurotransmitter receptors and transporters","volume":"374","author":"Torralva","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002052_bib26","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1007\/s00204-020-02855-7","article-title":"In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances","volume":"94","author":"Vandeputte","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1124\/jpet.123.002052_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","article-title":"Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole \u2018nitazene\u2019 synthetic opioid","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch Toxicol"},{"key":"10.1124\/jpet.123.002052_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109939","article-title":"Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide","volume":"249","author":"Vandeputte","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.123.002052_bib29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.123.002052_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00213-022-06292-5","article-title":"Plasma pharmacokinetics and pharmacodynamic effects of the 2-benzylbenzimidazole synthetic opioid, isotonitazene, in male rats","volume":"240","author":"Walton","year":"2023","journal-title":"Psychopharmacology (Berl)"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652417245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652417245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.002052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:18:47Z","timestamp":1739960327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652417245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S002235652417245X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.002052","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Characterization of Substituted Nitazenes at \u03bc, \u03ba, and \u0394 Opioid Receptors Suggests High Potential for Toxicity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.002052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}